Agus DB, Gordon MS, Taylor C, Natale RB, Karlan B, Mendelson DS, Press MF, Allison DE, Sliwkowski MX, Lieberman G, Kelsey SM, Fyfe G. Phase I clinical study of pertuzumab, a novel her dimerization inhibitor, in patients with advanced cancer. J Clin Oncol 2005;23:2534-2543.

Andersen MR, Nelson J, Peacock S, Giedzinska A, Dresher C, Bowen D, Urban N. Worry about ovarian cancer risk, and use of screening by high-risk women: how you recruit affects what you find. Am J Med Genet. 2004 Aug 30;129A(2):130-5.

Andersen MR, Urban N, Ramsey S, Briss PA. Examining the cost-effectiveness of cancer screening promotion. Cancer. 2004 Sep 1;101 Suppl 5:1229-38.

Andersen MR, Schroeder T, Gaul M, Moinpour C, Urban N. Using a population-based cancer registry for recruitment of newly diagnosed patients with ovarian cancer. Am J Clin Oncol. 2005 Feb;28(1):17-20.

Arboleda MJ, Lyons JF, Kabbinavar FF, Bray MR, Snow BE, Ayala R, Danino M, Karlan BY, Slamon DJ. Overexpression of AKT2/protein kinase Bbeta leads to up‑regulation of beta1 integrins, increased invasion, and metastasis of human breast and ovarian cancer cells.  Cancer Res 63:196‑206; 2003.

Baldwin RL, Tran H, Karlan BY. Loss of c-myc repression coincides with ovarian cancer resistance to transforming growth factor beta growth arrest independent of transforming growth factor beta/Smad signaling. Cancer Res. 2003 Mar 15;63(6):1413-9.

Balkwill FR, Ashworth A, Bast RC, Berek JS, Boyd J, Disis ML, Gabra H, Gore ME, Hamilton TC, Jacobs IJ, Kaye SB, Kohn EC, Mills GB, Urban ND. 10th Biennial Helene Harris Memorial Trust meeting. Cancer Res. 2006 Mar 15;66(6):2904-6.

Balkwill F, Bast RC, Berek J, Chenevix-Trench G, Gore M, Hamilton T, Jacobs I, Mills G, Souhami R, Urban N, Orsulic S, Smyth J. Current research and treatment for epithelial ovarian cancer. A Position Paper from the Helene Harris Memorial Trust. Eur J Cancer. 2003 Sep;39(13):1818-27.

Bast RC Jr, Lilja H, Urban N, Rimm DL, Fritsche H, Gray J, Veltri R, Klee G, Allen A, Kim N, Gutman S, Rubin MA, Hruszkewycz A. Translational crossroads for biomarkers. Clin Can Research, 2005 Sep 1;11(17):6103-8. Review.

Berek JS, Taylor PT, Gordon A, Cunningham MJ, Finkler N, Orr J Jr, Rivkin S, Schultes BC, Whiteside TL, Nicodemus CF. Randomized, placebo-controlled study of oregovomab for consolidation of clinical remission in patients with advanced ovarian cancer. J Clin Oncol. 2004 Sep 1;22(17):3507-16.

Boguski MS, McIntosh MW., Biomedical informatics for Proteomics, Nature/Insight, Vol 422, No. March, 2003, 43-47.

Brown JV 3rd, Peters WA 3rd, Rettenmaier MA, Graham CL, Smith MR, Drescher CW, Micha JP. Three-consecutive-day topotecan is an active regimen for recurrent epithelial ovarian cancer. Gynecol Oncol. 2003 Feb;88(2):136-40.

Byrne JA, Balleine RL, Fejzo MS, Mercieca J, Chiew YE, Livnat Y, St Heaps L, Peters GB, Byth K, Karlan BY, Slamon DJ, Harnett P, Defazio A. Tumor protein D52 (TPD52) is overexpressed and a gene amplification target in ovarian cancer. In Press: International J of Cancer, 2005.

Cass I, Baldwin RL, Varkey T, Moslehi R, Narod SA, Karlan BY.: Improved survival in BRCA associated ovarian cancer.  Cancer, 2003; 97: 2187-95.

Cass I, Holschneider C, Datta N, Barbuto D, Walts AE, Karlan BY. BRCA-mutation association fallopian tube carcinoma: a distinct clinical phenotype.  Obstet Gynecol. 2005 Dec;106(6):1327-34

Chen LM, Yamada SD, Fu YS, Baldwin RL, Karlan BY. Molecular similarities between primary peritoneal and primary ovarian carcinomas. Int J Gynecol Cancer. 2003 Nov-Dec;13(6):749-55.

Chiang JW, Karlan BY, Cass L, Baldwin RL.  BRCA1 promoter methylation predicts adverse ovarian cancer prognosis.Gynecol Oncol. 2005 Dec 14; [Epub ahead of print]

Chlebowski RT, Chen Z, Anderson GL, Rohan T, Aragaki A, Lane D, Dolan NC, Paskett ED, McTiernan A, Hubbell FA, Adams-Campbell LL, Prentice R. Ethnicity and breast cancer: factors influencing differences in incidence and outcome. J Natl Cancer Inst. 2005 Mar 16;97(6):439-48.

Curiel TJ, Coukos G, Zou L, Alvarez X, Cheng P, Mottram P, Evdemon-Hogan M, Conejo-Garcia JR, Zhang L, Burow M, Zhu Y, Wei S, Kryczek I, Daniel B, Gordon A, Myers L, Lackner A, Disis ML, Knutson KL, Chen L, Zou W. 6+Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med. 2004 Sep;10(9):942-9. Epub 2004 Aug 22.

Danke NA, Koelle DM, Yee C, Beheray S, Kwok WW. Autoreactive T cells in healthy individuals. J Immunol. 2004 May 15;172(10):5967-72.

Disis ML, Shiota FM, McNeel DG, Knutson KL. Soluble cytokines can act as effective adjuvants in plasmid DNA vaccines targeting self tumor antigens.  Immunobiology, 2003;207(3):179-86.

Disis ML, Rivkin S. Future directions in the management of ovarian cancer. Hematol Oncol Clin North Am. 2003 Aug;17(4):1075-85.

Disis ML, Scholler N, Dahlin A, Pullman J, Knutson KL, Hellstrom KE, Hellstrom I. Plasmid-based vaccines encoding rat neu and immune stimulatory molecules can elicit rat neu-specific immunity. Mol Cancer Ther. 2003 Oct;2(10):995-1002.

Disis ML, Schiffman K, Guthrie K, Salazar LG, Knutson KL, Goodell V, dela Rosa C, Cheever MA. Effect of dose on immune response in patients vaccinated with an her-2/neu intracellular domain protein--based vaccine. J Clin Oncol. 2004 May 15;22(10):1916-25.

Disis ML, Goodell V, Schiffman K, Knutson KL. Humoral epitope spreading following immunization with a HER-2/neu peptide based vaccine in cancer patients.  J. Clin Immunol. 2004 Sep;24(5):571-8.   

Doherty JA, Weiss NS, Freeman RJ, Dightman DA, Thornton PJ, Houck JR, Voigt LF, Rossing MA, Schwartz SM, Chen C. Genetic factors in catechol estrogen metabolism in relation to the risk of endometrial cancer. Cancer Epidemiol Biomarkers Prev. 2005 Feb;14(2):357-66.

Drescher CW, Nelson J, Peacock S, Andersen MR, McIntosh MW, Urban N. Compliance of average- and intermediate-risk women to semiannual ovarian cancer screening. Cancer Epidemiol Biomarkers Prev. 2004 Apr;13(4):600-6.

Elkas JC, Holschneider CH, Katz B, Li AJ, Louie R, McGonigle KF, Berek JS. The use of continuous infusion topotecan in persistent and recurrent ovarian cancer.  Int J Gynecol Cancer. 2003 Mar-Apr;13(2):138-41.

Elkas JC, Berek JS, Leuchter R, Lagasse LD, Karlan BY. Lower urinary tract reconstruction with ileum in the treatment of gynecologic malignancies.   Submitted: Gynecol Oncol, 2004

Erkanli A, Taylor DD, Dean D, Eksir F, Egger D, Geyer J, Nelson BH, Stone B, Fritsche HA, Roden RB.Application of Bayesian modeling of autologous antibody responses against ovarian tumor-associated antigens to cancer detection. Cancer Res. 2006 Feb 1;66(3):1792-8.

Etzioni R, Urban N, Ramsey S, McIntosh M, Schwartz S, Reid B, Radich J, Anderson G, Hartwell L. The case for early detection. Nat Rev Cancer. 2003 Apr;3(4):243-52. Review.   

Feng Q, Balasubramanian A, Hawes SE, Toure P, Sow PS, Dem A, Dembele B, Critchlow CW, Xi L, Lu H, McIntosh MW, Young AM, Kiviat NB. Detection of hypermethylated genes in women with and without cervical neoplasia. J Natl Cancer Inst. 2005 Feb 16;97(4):273-82.

Gass M, Anderson GL, Barad D. Concerns about published data from the estrogen-progestin (HT) arm of the WHI. Am J Obstet Gynecol. 2005 Jan;192(1):333.

Goodell V, Salazar LG, Urban N, Drescher CW, Gray H, Swensen RE, McIntosh MW, Disis ML Antibody Immunity to the p53 Oncogenic Protein Is a Prognostic Indicator in Ovarian Cancer. J Clin Oncol. 2006 Feb 10;24(5):762-8.

Groh V, Li YQ, Cioca D, Hunder NN, Wang W, Riddell SR, Yee C, Spies T. Efficient cross-priming of tumor antigen-specific T cells by dendritic cells sensitized with diverse anti-MICA opsonized tumor cells.  Proc Natl Acad Sci U S A. 2005 May 3;102(18):6461-6. Epub 2005 Apr 11.

Hellstrom KE, Hellstrom I. Therapeutic vaccination with tumor cells that engage CD137. Journal of Molecular Medicine 81:71-86, 2003.

Hellstrom KE, Hellstrom I. Novel approaches to therapeutic cancer vaccines. Expert Reviews on Vaccines. Future Drugs, pp 89-104. 2003.

Hellstrom KE, Hellstrom I. Novel approaches to therapeutic cancer vaccines. Expert Rev Vaccines. 2003 Aug;2(4):517-32.

Hellstrom I, Raycraft J, Hayden-Ledbetter M, Ledbetter JA, Schummer M, McIntosh M, Drescher C, Urban N, Hellstrom KE.. The HE4 (WFDC2) Protein is a Biomarker for Ovarian Carcinoma. Cancer Research, 2003 Jul 1;63(13):3695-700.

Ho WY, Blattman JN, Dossett ML, Yee C, Greenberg PD.. Adoptive immunotherapy: engineering T cell responses as biologic weapons for tumor mass destruction. Cancer Cell. 2003 May;3(5):431-7. Review.

Hwang H, Quenneville L, Yaziji H, Gown AM. Wilms tumor gene product: sensitive and contextually specific marker of serous carcinomas of ovarian surface epithelial origin. Appl Immunohistochem Mol Morphol. 2004 Jun;12(2):122-6.

Hood L, Heath JR, Phelps ME, Lin B. Systems biology and new technologies enable predictive and preventative medicine. Science, 306: 640-643, 2004.

Karlan B. Profiling the perpetrator. J Clin Oncol. 2004 Dec 1;22(23):4663-4.

Karlan BY. Defining cancer risks for BRCA germline mutation carriers: implications for surgical prophylaxis. Gynecol Oncol. 2004 Feb;92(2):519-20.

Kaufman HL, Disis ML. Immune system versus tumor: shifting the balance in favor of DCs and effective immunity. J Clin Invest. 2004 Mar;113(5):664-7.

Knutson KL, Curiel TJ, Salazar L, Disis ML. Immunologic principles and immunotherapeutic approaches in ovarian cancer. Hematol Oncol Clin North Am. 2003 Aug;17(4):1051-73.

Knutson KL, Almand B, Dang Y, Disis ML. Neu antigen-negative variants can be generated after neu-specific antibody therapy in neu transgenic mice. Cancer Res. 2004 Feb 1;64(3):1146-51.

Knutson KL, Disis ML. IL-12 enhances the generation of tumour antigen-specific Th1 CD4 T cells during ex vivo expansion. Clin Exp Immunol. 2004 Feb;135(2):322-9.

Knutson KL, Disis ML. Tumor antigen-specific T helper cells in cancer immunity and immunotherapy. Cancer Immunol Immunother. 2005 Jan 27; [Epub ahead of print].

Levine DA, Bogomolniy F, Yee CJ, Lash A, Barakat RR, Borgen PI, Boyd J. Frequent mutation of the PIK3CA gene in ovarian and breast cancers.Clin Cancer Res. 2005 Apr 15;11(8):2875-8.

Li AJ, Baldwin RL, Karlan BY. Estrogen and progesterone receptor subtype expression in normal and malignant ovarian epithelial cell cultures. Am J Obstet Gynecol. 2003 Jul;189(1):22-7.

Li AJ, Baldwin RL, Karlan BY.  Short androgen receptor allele length is a poor prognostic factor in epithelial ovarian carcinoma. Clin Cancer Res. 2003 Sep 1;9(10 Pt 1):3667-73.

Li Y, Bleakley M, Yee C. IL-21 Influences the Frequency, Phenotype, and Affinity of the Antigen-Specific CD8 T Cell Response.J Immunol. 2005 Aug 15;175(4):2261-9.

Li AJ, Giuntoli RL 2nd, Drake R, Byun SY, Rojas F, Barbuto D, Klipfel N, Edmonds P, Miller DS, Karlan BY..  Ovarian Preservation in Stage I Low-Grade Endometrial Stromal Sarcomas. Obstet Gynecol. 2005 Dec;106(6):1304-1308.

Li AJ, Lerner DL, Gapuzan ME, Karlan BY. AIB1 polymorphisms predict aggressive ovarian cancer phenotype. Cancer Epidemiol Biomarkers Prev. 2005 Dec;14(12):2919-22.

Li AJ, Karlan BY.  Androgen mediation of thrombocytosis in epithelial ovarian cancer biology. Clin Cancer Res. 2005 Nov 15;11(22):8015-8.

Li AJ, Madden AC, Cass I, Leuchter RS, Lagasse LD, Karlan BY. The prognostic significance of thrombocytosis in epithelial ovarian carcinoma. Gynecol Oncol. 2004 Jan;92(1):211-4.

Liao X, Li Y, Bonini C, Nair S, Gilboa E, Greenberg PD, Yee C. Transfection of RNA encoding tumor antigens following maturation of dendritic cells leads to prolonged presentation of antigen and the generation of high-affinity tumor-reactive cytotoxic T lymphocytes. Mol Ther. 2004 May;9(5):757-64.

Liede A, Karlan BY, Narod SA. Cancer risks for male carriers of germline mutations in BRCA1 or BRCA2: a review of the literature. J Clin Oncol. 2004 Feb 15;22(4):735-42.

Littman AJ, Rossing MA, Madeleine MM, Tang MT, Yasui Y. Association between late age at infectious mononucleosis, Epstein-Barr virus antibodies, and ovarian cancer risk. Scand J Infect Dis. 2003;35(10):728-35.

Lu KH, Patterson AP, Wang L, Marquez RT, Atkinson EN, Baggerly KA, Ramoth LR, Rosen DG, Liu J, Hellstrom I, Smith D, Hartmann L, Fishman D, Berchuck A, Schmandt R, Whitaker R, Gershenson DM, Mills GB, Bast RC Jr. Selection of potential markers for epithelial ovarian cancer with gene expression arrays and recursive descent partition analysis. Clin Cancer Res. 2004 May 15;10(10):3291-300.

McIntosh MW, Drescher C, Karlan B, Scholler N, Urban N, Hellstrom KE, Hellstrom I. Combining CA 125 and SMR serum markers for diagnosis and early detection of ovarian carcinoma. Gynecol Oncol. 2004 Oct;95(1):9-15.

Modugno F, Moslehi R, Ness RB, Nelson DB, Belle S, Kant JA, Wheeler JE, Wonderlick A, Fishman D, Karlan B, Risch H, Cramer DW, Dube MP, Narod SA. Reproductive factors and ovarian cancer risk in Jewish BRCA1 and BRCA2 mutation carriers (United States). Cancer Causes Control. 2003 Jun;14(5):439-46.

Montgomery RB, Makary E, Schiffman K, Goodell V, Disis ML.  Endogenous anti-HER2 antibodies block HER2 phosphorylation and signaling through extracellular signal-regulated kinase. Cancer Res. 2005 Jan 15;65(2):650-6.

Nelson BH. Interleukin-2, regulatory T cells and tolerance. Journal of Immunology. 2004 172:3983-8.

Peethambaram PP, Cliby WA, Lubiniecki G, Clayton AC, Roche PC, Iturria SJ, Hartmann LC, Hellstrom I, Strome SE. Her-2/neu expression in ovarian cancer: pre- and postexposure to platinum chemotherapy. Gynecol Oncol. 2003 Apr;89(1):99-104.

Pepe MS, Longton G, Anderson GL, Schummer M. Selecting Differentially Expressed Genes from Microarray Experiments. Biometrics 59:133-142, 2003.

Pepe MS, Longton G. Standardizing diagnostic markers to evaluate and compare their performance.
Epidemiology. 2005 Sep;16(5):598-603.

Robinson BW, Creaney J, Lake R, Nowak A, Musk AW, de Klerk N, Winzell P, Hellstrom KE, Hellstrom I. Mesothelin-family proteins and diagnosis of mesothelioma. Lancet. 2003 Nov 15;362(9396):1612-6.

Rosen DG, Wang L, Atkinson JN, Yu Y, Lu KH, Diamandis EP, Hellstrom I, Mok SC, Liu J, Bast RC Jr. Potential markers that complement expression of CA125 in epithelial ovarian cancer. Gynecol Oncol. 2005 Jul 29; [Epub ahead of print]

Rossing MA, Tang MT, Flagg EW, Weiss LK, Wicklund KG. A case-control study of ovarian cancer in relation to infertility and the use of ovulation-inducing drugs. Am J Epidemiol. 2004 Dec 1;160(11):1070-8.

Roszkowski JJ, Lyons GE, Kast WM, Yee C, Van Besien K, Nishimura MI.Simultaneous generation of CD8+ and CD4+ melanoma-reactive T cells by retroviral-mediated transfer of a single T-cell receptor.Cancer Res. 2005 Feb 15;65(4):1570-6.

Sabbatini P, Aghajanian C, Dizon D, Anderson S, Dupont J, Brown JV, Peters WA, Jacobs A, Mehdi A, Rivkin S, Eisenfeld AJ, Spriggs D. Phase II study of CT-2103 in patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal carcinoma. J Clin Oncol. 2004 Nov 15;22(22):4523-31.

Salazar LG, Fikes J, Southwood S, Ishioka G, Knutson KL, Gooley TA, Schiffman K, Disis ML. Immunization of cancer patients with HER-2/neu-derived peptides demonstrating high-affinity binding to multiple class II alleles. Clin Cancer Res. 2003 Nov 15;9(15):5559-65.

Scholler N, Crawford M, Sato A, Drescher CW, O'Briant KC, Kiviat N, Anderson GL, Urban N. Bead-Based ELISA for Validation of Ovarian Cancer Early Detection Markers.Clin Cancer Res. 2006 Apr 1;12(7):2117-2124.

Sova P, Feng Q, Geiss G, Wood T, Strauss R, Rudolf V, Lieber A, Kiviat N. Discovery of novel methylation biomarkers in cervical carcinoma by global demethylation and microarray analysis. Cancer Epidemiol Biomarkers Prev. 2006 Jan;15(1):114-23. 

Sova P, Ren XW, Ni S, Bernt KM, Mi J, Kiviat N, Lieber A. A tumor-targeted and conditionally replicating oncolytic adenovirus vector expressing TRAIL for treatment of liver metastases. Molecular Therapy. 2004 9: 496-509.

Stewart JJ, White JT, Yan X, Collins S, Drescher CW, Urban ND, Hood L, Lin B. Proteins associated with cisplatin resistance in ovarian cancer cells identified by quantitative proteomics technology and integrated with mRNA expression levels. Mol Cell Proteomics. 2005 Mar 1: 5(3): 433-43.

Stone B, Schummer M, Paley PJ, Thompson L, Stewart J, Ford M, Crawford M, Urban N, O'Briant K, Nelson BH. Serologic analysis of ovarian tumor antigens reveals a bias toward antigens encoded on 17q. Int J Cancer. 2003 Mar 10;104(1):73-84.

Swisher E. Ovarian cancer associated with inherited mutations in BRCA1 or BRCA2. Curr Womens Health Rep. 2003 Feb;3(1):27-32. Review.

Swisher E. Prophylactic surgery and other strategies for reducing the risk of familial ovarian cancer. Curr Treat Options Oncol. 2003 Apr;4(2):105-10. Review.

Swisher E. Comment on "Malignant mixed Mullerian tumor of the ovary: an argument for BRCA3 or a coincidental cluster of unconnected cancer". Gynecol Oncol. 2004 Dec;95(3):773-4; author reply 774.

Swisher EM, Wollan M, Mahtani SM, Willner JB, Garcia R, Goff BA, King MC. Tumor-specific p53 sequences in blood and peritoneal fluid of women with epithelial ovarian cancer.Am J Obstet Gynecol. 2005 Sep;193(3 Pt 1):662-7.

Teague RM, Tempero RM, Thomas S, Murali-Krishna K, Nelson BH. Proliferation and Differentiation of CD8⁺ T Cells in the Absence of IL 2/15 Receptor Chain Expression or STAT5 Activation. Journal of Immunology.  2004 Sep 1;173(5):3131-3139.

Urban N. Specific keynote: ovarian cancer risk assessment and the potential for early detection. Gynecol Oncol. 2003 Jan;88 (1 Pt 2):S75-9; discussion S80-3. Review.

Urban N, McIntosh MW, Andersen M, Karlan BY. Ovarian Cancer Screening. Hematol Oncol Clin N Am. 2003 Aug;17(4):989-1005, ix.

Yang S, Yang Y, Raycraft J, Zhang H, Kanan S, Guo Y, Ronai Z, Hellstrom I, Hellstrom KE.: Melanoma cells transfected to express CD83 induce anti-tumor immunity that can be increased by also engaging CD137. Proc. Natl. Acad. Sci., 101, 4990-4995, 2004.

Yaziji H, Battifora H, Barry TS, Hwang HC, Bacchi CE, McIntosh MW, Kussick SJ, Gown AM. Evaluation of 12 antibodies for distinguishing epithelioid mesothelioma from adenocarcinoma: identification of a three-antibody immunohistochemical panel with maximal sensitivity and specificity. Mod Pathol. 2006 Apr;19(4):514-23.

Yee C. Adoptive T cell therapy: Addressing challenges in cancer immunotherapy. J Transl Med. 2005 Apr 28;3(1):17.

Andersen MR, Drescher CW, Zheng Y, Bowen DJ, Wilson S, Young A, McIntosh M, Mahony BS, Urban N. Changes in Cancer Worry Associated with Participation in Ovarian Cancer Screening. [Submitted to Lancet Oncology]

Andersen MR, Abullarade J, Urban N. Assertiveness with Physicians Is Related to Women's Perceived Roles in the Medical Encounter. Women Health. 2005;42(2):15-33. PMID: 16537298 [PubMed - in process]

Berchuck A, Mutch DG, Karlan BY. The how, when and why of surgical prophylaxis in the high risk patient: Hereditary ovarian and endometrial cancer.  In Press: J Clin Oncol, 2005.

Hellstrom, I, Raycraft, J, Hellstrom, K.E.: Serum assays for diagnosis of ovarian cancer and mesothelioma: An overview. J. Clinical Ligand Assay 26, in press, 2004.

Holschneider CH, Baldwin RL, Tumber K, Aoyama C, Karlan BY. The fragile histidine triad (FHIT) gene expression may link cigarette smoking and cervical cancer.  Submitted: Clin Cancer Res, 2004.

Holschneider CH, Manuel MR, Karlan BY, Williams CM, Waxman AD. FDG-PET in ovarian cancer: The use of the standardized uptake value (SUV) to differentiate physiological bowel activity from intraperitoneal metastatic tumor.  Submitted: J Nuclear Med, 2004.

Iyer, S., Deutsch, K., and Lin, B. Batch RNAi Selector: a standalone program to predict specific siRNA candidates in batches with enhanced sensitivity. BMC Bioinformatics, submitted, 2005.

Li, Z-Y., Strauss, R., Sova, P., Ni, S., Shayakhmetov, D., Urban, N., Lieber, A. Enrichment and characterization of ovarian cancer stem cells, in process.

Lin B, Price N, Stewart J, Yan X, Utleg A, Guo Z, White J, Lu W, O’Briant K, McIntosh M, Shmulevich I, Collins S, Urban N, Drescher C, Hood L.   Hyaluronidase 2 expression levels predict chemotherapy responses in ovarian cancers, in process

Lu, W., Zheng, W., Yan, X., White, JT. Urban, N., Drescher, C., Zhou, D., Hood, L. and Lin, B.  Pathways related to induced chemotherapy resistance to cisplatin revealed by MPSS analysis of ovarian cancer cells.  In process.

Strauss, R., Sova, P., Liu, Y., Li, Z., Urban, N., Kiviat, N., Lieber, A. Resistance of primary ovarian cancer cells to viral oncolysis, in process.